Radio and PodcastRadio and PodcastLive Radio & Podcasts
FDA investigating risk of severe hypocalcemia in patients on dialysis receiving osteoporosis medicine Prolia (denosumab) artwork
Science & Medicine

FDA investigating risk of severe hypocalcemia in patients on dialysis receiving osteoporosis medicine Prolia (denosumab)

FDA Drug Safety Podcasts by U.S. Food and Drug Administration, Center for Drug Evaluation and Research

Dec 16, 20224:00Science & Medicine

FDA investigating risk of severe hypocalcemia in patients on dialysis receiving osteoporosis medicine Prolia (denosumab)

About This Episode

FDA investigating risk of severe hypocalcemia in patients on dialysis receiving osteoporosis medicine Prolia (denosumab) is an episode from FDA Drug Safety Podcasts by U.S. Food and Drug Administration, Center for Drug Evaluation and Resear...

Podcast

This episode belongs to FDA Drug Safety Podcasts.

Listen Online

Use the player on this page to stream the episode online.

Episode Details

Published Dec 16, 2022, 4:00 long, audio available.

Related Episodes

Continue listening to more episodes from FDA Drug Safety Podcasts.

Questions About This Episode

What is FDA investigating risk of severe hypocalcemia in patients on dialysis receiving osteoporosis medicine Prolia (denosumab) about?

FDA investigating risk of severe hypocalcemia in patients on dialysis receiving osteoporosis medicine Prolia (denosumab)

Where can I listen to FDA investigating risk of severe hypocalcemia in patients on dialysis receiving osteoporosis medicine Prolia (denosumab)?

You can listen to FDA investigating risk of severe hypocalcemia in patients on dialysis receiving osteoporosis medicine Prolia (denosumab) online on Radio and Podcast. Open the player on this page to stream the available audio.

Which podcast is FDA investigating risk of severe hypocalcemia in patients on dialysis receiving osteoporosis medicine Prolia (denosumab) from?

FDA investigating risk of severe hypocalcemia in patients on dialysis receiving osteoporosis medicine Prolia (denosumab) is an episode from FDA Drug Safety Podcasts by U.S. Food and Drug Administration, Center for Drug Evaluation and Research.

How long is this episode?

This episode is 4:00 long.

When was this episode published?

This episode was published on Dec 16, 2022.

Can I save FDA investigating risk of severe hypocalcemia in patients on dialysis receiving osteoporosis medicine Prolia (denosumab) for later?

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Are there related episodes from FDA Drug Safety Podcasts?

Yes. This page shows related episodes from FDA Drug Safety Podcasts when more episodes are available from the podcast feed.

Quick Answers About This Episode

Where can I listen to FDA investigating risk of severe hypocalcemia in patients on dialysis receiving osteoporosis medicine Prolia (denosumab)?

You can listen to FDA investigating risk of severe hypocalcemia in patients on dialysis receiving osteoporosis medicine Prolia (denosumab) on this page when the episode audio is available from the podcast feed.

Which podcast is this episode from?

FDA investigating risk of severe hypocalcemia in patients on dialysis receiving osteoporosis medicine Prolia (denosumab) is from FDA Drug Safety Podcasts by U.S. Food and Drug Administration, Center for Drug Evaluation and Research.

What are the episode details?

Published Dec 16, 2022 and 4:00 long